慢性房颤华法令抗凝治疗的理想INR值探讨

目的:探讨慢性房颤华法令抗凝治疗的理想国际标准化比值(INR)。方法:对115例有血栓栓塞高危因素的慢性房颤患者给予华法令抗凝治疗,定期随访INR,同时观察治疗中发生的血栓栓塞和出血事件。结果:115例患者中有8例共10次发生血栓栓塞事件,7例7次发生与抗凝有关的出血事件,10次血栓栓塞事件中9次发生在INR<1.7,而所有的出血事件都发生在INR>3.5,INR 1.7～3.5时栓塞或出血发生率均较低。结论:INR 1.7～3.5是慢性房颤华法令抗凝治疗较理想的抗凝强度。

Study of the optimal range of international normalized ratio(INR)for patients with chronic atrial fibrillation receiving warfarin for anticoagulation

Objective:To study the optimal range of international normalized ratio(INR) for patients with chronic atrial fibrillation receiving warfarin for anticoagulation.Methods:115 patients with chronic atrial fibrillation all received warfarin for anticoagulation.The INR was regularly followed up and the events of thromboembolism and the INR-specific of haemorrhagia were calculated.Results:Eight of the 115 patients experienced 10 thromboembolic events and seven patients experienced 7 haemorrhagic events.Nine of 10 thromboembolic events occurred at INR<1.7 and all haemorrhagic events occurred at INR>3.5.The incidence rate of either haemorrhagic or thromboembolic events was lowest at INR between 1.7 and 3.5.Conclusion:INR of 1.7~3.5 appeared to be the optimal range of INR associated with the lowest incidence rate of major haemorrhagic or thromboembolic events for patients with chronic atrial fibrillation receiving warfarin for anticoagulation.